ESMO 2019: “IMvigor130 will change clinical practice”

Richard Cathomas, MD, of Kantonsspital Graubünden, on this year’s highlights of genitourinary cancers: RADICALS-RT, ARTISTIC and PROfound.

Abstracts, die im Video diskutiert werden:

  • Parker C et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): Firstresults from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]. # LBA49_PR
  • Vale CL et al. Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis. LBA48_PR
  • Hussain M et al. PROFOUND: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (MCRPC) with homologous recombination repair (HRR) gene alterations. #LBA12_PR
  • De Wit R et al. CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). #LBA13
  • Grande E et al. IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). #LBA14_PR

ESMO Congress 2019